KREJČÍ, Marta, Andrea JANÍKOVÁ, František FOLBER, Zdeněk KRÁL a Jiří MAYER. Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety. Neoplasma. Bratislava: Slovenská akademie vied, 2015, roč. 62, č. 5, s. 787-792. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2015_094.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety
Autoři KREJČÍ, Marta (203 Česká republika, garant, domácí), Andrea JANÍKOVÁ (203 Česká republika, domácí), František FOLBER (203 Česká republika, domácí), Zdeněk KRÁL (203 Česká republika, domácí) a Jiří MAYER (203 Česká republika, domácí).
Vydání Neoplasma, Bratislava, Slovenská akademie vied, 2015, 0028-2685.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Slovensko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 1.961
Kód RIV RIV/00216224:14110/15:00084608
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.4149/neo_2015_094
UT WoS 000362389600013
Klíčová slova anglicky sibling donor; PBSC mobilization; G-CSF
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 10. 11. 2015 10:01.
Anotace
Mobilization of peripheral blood stem cells (PBSC) using the granulocyte colony-stimulating factor (G-CSF) has enabled the collection even from older donors and those with comorbidities. Several clinical parameters have been reported to predict the success of PBSC mobilization. The aim of our study was to evaluate the safety of PBSC donation in a cohort of 167 sibling donors after mobilization with G-CSF 16 mu g/kg/day for 5 days during short- and long term follow-up and to analyse the efficacy, toxicity and factors influencing CD34+ mobilization capacity. All 167 sibling donors completed the established mobilization protocol. The median yield was 7.9x10(6)CD34 cells/kg per recipient weight. The optimal target dose of CD34 cells >= 4.0x10(6)/kg was achieved in 140 donors (84%). Only in 4 donors (2%) was the CD34+ yield < 2x10(6)/kg. No major toxicities occured. Factors associated with higher PBSC yields included age < 55 years (p=0.001), male gender (p=0.004), preapheresis CD34 cell counts > 51/mu L (p < 0.001) and preapheresis leukocyte counts >45.5 x 10(9)/L (p =0.003). Comorbidity score, performance status and donor weight did not significantly influence PBSC yields. Long-term follow-up was possible in 60% (101/167) of the donors. The median length of follow-up from PBSC donation was 11.9 years. Most of these donors reported good or very good general health (91%), and no hematological malignancies were observed. The mobilization of PBSC in sibling donors with G-CSF 16 mu g/kg/day is an effective and safe procedure with no significant short- and long-term toxicities.
VytisknoutZobrazeno: 4. 7. 2024 00:12